Pluri Inc. (PLUR) Dividend History

Company News

• DarioHealth Announces CFO Transition

  DarioHealth Corp. announced that its Chief Financial Officer, Zvi Ben-David, will retire on May 15, 2025. The company has appointed Chen Franco-Yehuda as the new CFO, Treasurer, and Secretary, effective upon Ben-David's retirement.

  Benzinga

  Featured Companies: BNRG DRIO
• Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

  Pluri Inc. announced a $6.5 million strategic investment and the acquisition of a 71% stake in Kokomodo Ltd., an AgTech company focused on cultivated cacao production. The transactions aim to strengthen Pluri's financial position and expand its leadership in sustainable food technologies.

  Benzinga
• Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com

  Pluri Inc., a biotechnology firm, is facing the possibility of being delisted from the Nasdaq Capital Market due to failing to meet the minimum stockholders' equity requirement. The company has submitted a compliance plan and has been granted an extension until November 2024 to regain compliance.

  Investing.com
• Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

  HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri’s subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri’s majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri’s technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods’ cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.

  GlobeNewswire Inc.
• U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract

  HAIFA, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company), a leading biotechnology company that transforms cells into solutions, today announced the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023. During the 12 months from July 1, 2024 through June 30, 2025, the NIAID will provide $1.4 million for the Company to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).

  GlobeNewswire Inc.